Beam Therapeutics Inc

NASDAQ:BEAM

16.36

-0.49 (-2.91%)

7:58:27 PM EDT: $16.37 +0.01 (+0.06%)

Market Cap (Intraday)	1.61B
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$13.24 Million
Adjusted EPS	-$1.03

See more estimates

10-Day MA	$16.76
50-Day MA	$18.65
200-Day MA	$22.05

See more pivots

Beam Therapeutics Inc Stock, NASDAQ:BEAM

238 Main Street, 9th floor, Cambridge, Massachusetts 02142-1016

United States of America

Phone: +1.857.327.8775

Number of Employees: 483

http://www.beamtx.com

Description

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.